中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2015年
17期
2632-2634
,共3页
沙美特罗氟替卡松%哮喘%肺功能%C反应蛋白质
沙美特囉氟替卡鬆%哮喘%肺功能%C反應蛋白質
사미특라불체잡송%효천%폐공능%C반응단백질
Salmeterol fluticasone%Asthma%Lung function%C reaction protein
目的：探讨沙美特罗氟替卡松治疗哮喘的临床疗效及其对肺功能、血清C反应蛋白（CRP）的影响。方法将202例哮喘患者采用随机数字表法分为观察组与对照组，每组101例。对照组单纯给予丙酸氟替卡松吸入治疗，观察组给予沙美特罗氟替卡松吸入治疗。对两组患者治疗疗效及治疗前后肺功能、血清CRP的变化进行比较分析。结果观察组总有效率为92．1％，高于对照组的78．2％，两组差异有统计学意义（χ2＝3．842，P＜0．05）；治疗后，观察组用力肺活量（FVC）、第一秒用力呼气容积（FEV1）及最大呼气峰流速（PEF）分别为（84．11±16．25）％、（96．34±19．65）％、（93．14±17．85）％，对照组分别为（74．31±14．27）％、（84．36±20.31）％、（83．52±19．89）％，两组均较治疗前明显改善，且观察组改善程度明显优于对照组，差异均有统计学意义（t＝3．425、2．573、2．895，均P＜0．05）；治疗后，观察组CRP为（18．94±3．46）mg／L，对照组为（10．34±1.97）mg／L，与治疗前比较，两组CRP水平均有不同程度降低，观察组降低程度优于对照组（t＝2.874，P＜0.05）。结论沙美特罗氟替卡松吸入治疗哮喘能够显著提高临床疗效，改善患者肺功能及血清CRP水平。
目的：探討沙美特囉氟替卡鬆治療哮喘的臨床療效及其對肺功能、血清C反應蛋白（CRP）的影響。方法將202例哮喘患者採用隨機數字錶法分為觀察組與對照組，每組101例。對照組單純給予丙痠氟替卡鬆吸入治療，觀察組給予沙美特囉氟替卡鬆吸入治療。對兩組患者治療療效及治療前後肺功能、血清CRP的變化進行比較分析。結果觀察組總有效率為92．1％，高于對照組的78．2％，兩組差異有統計學意義（χ2＝3．842，P＜0．05）；治療後，觀察組用力肺活量（FVC）、第一秒用力呼氣容積（FEV1）及最大呼氣峰流速（PEF）分彆為（84．11±16．25）％、（96．34±19．65）％、（93．14±17．85）％，對照組分彆為（74．31±14．27）％、（84．36±20.31）％、（83．52±19．89）％，兩組均較治療前明顯改善，且觀察組改善程度明顯優于對照組，差異均有統計學意義（t＝3．425、2．573、2．895，均P＜0．05）；治療後，觀察組CRP為（18．94±3．46）mg／L，對照組為（10．34±1.97）mg／L，與治療前比較，兩組CRP水平均有不同程度降低，觀察組降低程度優于對照組（t＝2.874，P＜0.05）。結論沙美特囉氟替卡鬆吸入治療哮喘能夠顯著提高臨床療效，改善患者肺功能及血清CRP水平。
목적：탐토사미특라불체잡송치료효천적림상료효급기대폐공능、혈청C반응단백（CRP）적영향。방법장202례효천환자채용수궤수자표법분위관찰조여대조조，매조101례。대조조단순급여병산불체잡송흡입치료，관찰조급여사미특라불체잡송흡입치료。대량조환자치료료효급치료전후폐공능、혈청CRP적변화진행비교분석。결과관찰조총유효솔위92．1％，고우대조조적78．2％，량조차이유통계학의의（χ2＝3．842，P＜0．05）；치료후，관찰조용력폐활량（FVC）、제일초용력호기용적（FEV1）급최대호기봉류속（PEF）분별위（84．11±16．25）％、（96．34±19．65）％、（93．14±17．85）％，대조조분별위（74．31±14．27）％、（84．36±20.31）％、（83．52±19．89）％，량조균교치료전명현개선，차관찰조개선정도명현우우대조조，차이균유통계학의의（t＝3．425、2．573、2．895，균P＜0．05）；치료후，관찰조CRP위（18．94±3．46）mg／L，대조조위（10．34±1.97）mg／L，여치료전비교，량조CRP수평균유불동정도강저，관찰조강저정도우우대조조（t＝2.874，P＜0.05）。결론사미특라불체잡송흡입치료효천능구현저제고림상료효，개선환자폐공능급혈청CRP수평。
Objective To investigate the clinical curative effect of salmeterol fluticasone asthma and its in-fluence on lung function,serum CRP.Methods 202 cases of asthma patients were divided into the observation group and control group,with 101 cases in each group.The control group patients simply give fluticasone propionate inhala-tion therapy,the observation group patients were given salmeterol fluticasone inhalation therapy.Before and after treat-ment in patients with two groups of curative effect and treatment of pulmonary function,the change of serum CRP were compared.Results The total effective rate of the observation group was 92.1%,which was higher than the control group (78.2%)obviously,the difference was statistically significant(χ2 =3.842,P<0.05 ).After treatment,the forced vital capacity(FVC),forced expiratory volume in first second(FEV1 )and the maximum peak expiratory flow (PEF)of the observation group were respectively (84.11 ±16.25 )%,(96.34 ±19.65 )% and (93.14 ± 17.85)%,and the control group were respectively (74.31 ±14.27)%,(84.36 ±20.31)% and (83.52 ± 19.89)%,each group was obviously improved than before treatment,and the observation group improvement were better than the control group,the difference was statistically significant(t=3.425,2.573,2.895,all P<0.05).After treatment,the CRP of the observation group was (18.94 ±3.46 )mg/L,and the control group was (10.34 ± 1.97)mg/L,each group was obviously improved than before treatment,and the observation group improvement was better than the control group,the difference was statistically significant(t=2.874,P<0.05 ).Conclusion Salmet-erol fluticasone inhaled asthma can significantly improve the clinical curative effect to improve the patient's lung func-tion and serum CRP level,and is safe and reliable.It is worth widely application in the clinical practice.
